Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial

Hanne Lamberink; Sammy Huygens; Robina Aerts; Katrien Lagrou; Elena van Leeuwen-Segarceanu; Tom Lodewyck; Laurens Nieuwenhuizen; Maarten F Corsten; Ine Moors; Sophie Servais; Julien De Greef; Maya Hites; Astrid Demandt; Alexander Schauwvlieghe; Johan Maertens; Bart Rijnders

doi:10.1093/cid/ciae501

Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial

Hanne Lamberink, Sammy Huygens, Robina Aerts, Katrien Lagrou, Elena van Leeuwen-Segarceanu, Tom Lodewyck, Laurens Nieuwenhuizen, Maarten F Corsten, Ine Moors, Sophie Servais, Julien De Greef, Maya Hites, Astrid Demandt, Alexander Schauwvlieghe, Johan Maertens, Bart Rijnders^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.

Original language	English
Pages (from-to)	367-370
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	80
Issue number	2
Early online date	8 Oct 2024
DOIs	https://doi.org/10.1093/cid/ciae501
Publication status	Published - 15 Feb 2025

Keywords

azole
combination therapy
echinocandin
invasive aspergillosis

Access to Document

10.1093/cid/ciae501Licence: CC BY-NC-ND

Cite this

Lamberink, H., Huygens, S., Aerts, R., Lagrou, K., van Leeuwen-Segarceanu, E., Lodewyck, T., Nieuwenhuizen, L., Corsten, M. F., Moors, I., Servais, S., De Greef, J., Hites, M., Demandt, A., Schauwvlieghe, A., Maertens, J., & Rijnders, B. (2025). Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial. Clinical Infectious Diseases, 80(2), 367-370. https://doi.org/10.1093/cid/ciae501

@article{77ae32980f6e4ce5ae2eb4bb7155d071,

title = "Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial",

abstract = "The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.",

keywords = "azole, combination therapy, echinocandin, invasive aspergillosis",

author = "Hanne Lamberink and Sammy Huygens and Robina Aerts and Katrien Lagrou and \{van Leeuwen-Segarceanu\}, Elena and Tom Lodewyck and Laurens Nieuwenhuizen and Corsten, \{Maarten F\} and Ine Moors and Sophie Servais and \{De Greef\}, Julien and Maya Hites and Astrid Demandt and Alexander Schauwvlieghe and Johan Maertens and Bart Rijnders",

year = "2025",

month = feb,

day = "15",

doi = "10.1093/cid/ciae501",

language = "English",

volume = "80",

pages = "367--370",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "2",

}

Lamberink, H, Huygens, S, Aerts, R, Lagrou, K, van Leeuwen-Segarceanu, E, Lodewyck, T, Nieuwenhuizen, L, Corsten, MF, Moors, I, Servais, S, De Greef, J, Hites, M, Demandt, A, Schauwvlieghe, A, Maertens, J & Rijnders, B 2025, 'Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial', Clinical Infectious Diseases, vol. 80, no. 2, pp. 367-370. https://doi.org/10.1093/cid/ciae501

TY - JOUR

T1 - Superiority trials in invasive aspergillosis

T2 - a harsh reality check with the IA-DUET (HOVON502) trial

AU - Lamberink, Hanne

AU - Huygens, Sammy

AU - Aerts, Robina

AU - Lagrou, Katrien

AU - van Leeuwen-Segarceanu, Elena

AU - Lodewyck, Tom

AU - Nieuwenhuizen, Laurens

AU - Corsten, Maarten F

AU - Moors, Ine

AU - Servais, Sophie

AU - De Greef, Julien

AU - Hites, Maya

AU - Demandt, Astrid

AU - Schauwvlieghe, Alexander

AU - Maertens, Johan

AU - Rijnders, Bart

PY - 2025/2/15

Y1 - 2025/2/15

N2 - The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.

AB - The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.

KW - azole

KW - combination therapy

KW - echinocandin

KW - invasive aspergillosis

U2 - 10.1093/cid/ciae501

DO - 10.1093/cid/ciae501

M3 - Article

SN - 1058-4838

VL - 80

SP - 367

EP - 370

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 2

ER -

Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this